Mersana
Cambridge, US · Delaware corporation · 7 known investors
A biopharmaceutical company developing targeted oncology medicines, with a focus on treatments for patients of all ages including children with cancers such as pediatric low-grade glioma (pLGG). It uses a "search & development" strategy grounded in cancer biology to identify drug programs, and is part of Servier.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
MJ
MICHAEL J. KAUFMANNamed on SEC filing
DB
DONALD BERGSTROMNamed on SEC filing
AP
ANNA PROTOPAPASNamed on SEC filing
DM
DAVID MOTTNamed on SEC filing
TL
TIMOTHY LOWINGERNamed on SEC filing
EJ
EVA JACKNamed on SEC filing
SN
SARA NAYEEMNamed on SEC filing
WF
WAYNE FOSTERNamed on SEC filing
EJ
ELAINE JONESNamed on SEC filing
WF
Wayne FosterNamed on SEC filing
PP
Peter ParkNamed on SEC filing
NG
Nicholas G. BacopoulosNamed on SEC filing
Investors · 7
Reported raises · per SEC filings
Form D private placements$57.7M disclosed across 3 rounds · 2013–2016
▶$33.1MraisedJun 2016 · 13 investors · BiotechnologyRule 506(b)
▶$33.1MraisedJun 2016 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- TIMOTHY LOWINGERExecutive Officer
- DAVID MOTTDirector
- ELAINE JONESDirector
- MICHAEL J. KAUFMANExecutive Officer
- THOMAS BECKDirector
- ANNA PROTOPAPASExecutive Officer, Director
- EVA JACKExecutive Officer
- DONALD BERGSTROMExecutive Officer
- SARA NAYEEMDirector
- WAYNE FOSTERExecutive Officer
- Offering amount
- $33.1M
- Amount sold
- $33.1M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.1MraisedMar 2016 · 10 investors · BiotechnologyRule 506(b)
▶$10.1MraisedMar 2016 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL J. KAUFMANExecutive Officer
- DONALD BERGSTROMExecutive Officer
- ANNA PROTOPAPASExecutive Officer, Director
- DAVID MOTTDirector
- TIMOTHY LOWINGERExecutive Officer
- EVA JACKExecutive Officer
- SARA NAYEEMDirector
- THOMAS BECKDirector
- WAYNE FOSTERExecutive Officer
- ELAINE JONESDirector
- Offering amount
- $35.5M
- Amount sold
- $10.1M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedApr 2014 · 10 investors · BiotechnologyRule 506(b)
▶$14.5MraisedApr 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wayne FosterExecutive Officer
- Peter ParkExecutive Officer
- Nicholas G. BacopoulosDirector
- Timothy B. LowingerExecutive Officer
- Sara NayeemDirector
- David MottExecutive Officer, Director
- Donald BergstromExecutive Officer
- Thomas BeckDirector
- Eva JackExecutive Officer
- Offering amount
- $14.5M
- Amount sold
- $14.5M
- First sale
- Sep 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Mersana do?
- A biopharmaceutical company developing targeted oncology medicines, with a focus on treatments for patients of all ages including children with cancers such as pediatric low-grade glioma (pLGG). It uses a "search & development" strategy grounded in cancer biology to identify drug programs, and is part of Servier.
- Who are Mersana's investors?
- Mersana's investors include Bain Capital Life Sciences, F-Prime Capital Partners, Lightstone Ventures, New Enterprise Associates (NEA), Nextech Invest, Pfizer Venture Investments, Rho Ventures.
- How much funding has Mersana raised?
- Mersana has disclosed $57.7M raised across 3 rounds.
- Where is Mersana headquartered?
- Mersana is headquartered in Cambridge, US.